Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...

Regeneron Pharmaceuticals (NASDAQ: REGN) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Clinical laboratory professionals are transforming healthcare for expectant mothers and their babies, according to the special January issue of Clinical Chemistry published by the Association for ...

This event will highlight advances in developing and applying complex biological models, including patient-derived organoids, iPSC-based systems and CRISPR-edited constructs. Information you provide ...

The scientist quit the CDC in protest after Trump-appointed Secretary of Health and Human Services Robert F. Kennedy Jr. removed every member of the Advisory Community on Immunization Practices.

Copyright 2020 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals Stocks: Real-time U.S. stock quotes reflect trades reported through ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 96.18 with a ...